PROVIGIL Drug Patent Profile

Which patents cover Provigil, and what generic alternatives are available?

Provigil is a drug marketed by Nuvo Pharms and is included in one NDA.

The generic ingredient in PROVIGIL is modafinil. There are twenty-six drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the modafinil profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Provigil

A generic version of PROVIGIL was approved as modafinil by ORBION PHARMS on September 26^th, 2012.

Summary for PROVIGIL

US Patents:	0
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for PROVIGIL

US Patents and Regulatory Information for PROVIGIL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Nuvo Pharms	PROVIGIL	modafinil	TABLET;ORAL	020717-001	Dec 24, 1998	AB	RX	Yes	No
Nuvo Pharms	PROVIGIL	modafinil	TABLET;ORAL	020717-002	Dec 24, 1998	AB	RX	Yes	Yes

International Patents for PROVIGIL

See the table below for patents covering PROVIGIL around the world.

Country	Patent Number	Title	Estimated Expiration
Israel	158959	SOLID PHARMACEUTICAL FORMULATIONS COMPRISING MODAFINIL
Canada	2382275	MODAFINIL A GROSSEUR DE PARTICULE DEFINI (MODAFINIL HAVING DEFINED PARTICLE SIZE)
Mexico	PA03010705	FORMULACIONES FARMACEUTICAS SOLIDAS QUE COMPRENDEN MODAFINIL. (SOLID PHARMACEUTICAL FORMULATIONS COMPRISING MODAFINIL.)
European Patent Office	1397127	PREPARATIONS PHARMACEUTIQUES SOLIDES COMPRENANT DU MODAFINIL (SOLID PHARMACEUTUCAL FORMULATIONS COMPRISING MODAFINIL)
Italy	7821872
Portugal	731698

Last updated: February 3, 2026

mmary
Provigil (generic name: modafinil) continues to hold a prominent position within the wakefulness-promoting drug market, targeting conditions such as narcolepsy, shift work sleep disorder, and excessive daytime sleepiness associated with sleep apnea. The drug's patent expiration and its market potential in both prescription and off-label uses influence investment considerations. Analyzing its development history, regulatory landscape, competitive environment, and market trends provides a comprehensive view for investors and stakeholders.

---

What is the Current Market Status and Revenue Potential for Provigil?

Provigil is marketed by Cephalon (now part of Teva Pharmaceuticals since 2011) under the brand, generating significant revenues pre-patent expiration. The drug's sales peaked at approximately $1.2 billion in the US in 2010. Since patent expiry in June 2012, generic versions entered the market, resulting in a steep decline in brand sales.

Despite the decline, the drug maintains a substantial market share, driven by off-label uses such as cognitive enhancement and fatigue treatment in multiple settings, including military and corporate environments. Estimates suggest global sales of modafinil (brand plus generics) surpass $2 billion annually, with generics contributing to approximately 70% of the market volume.

Off-label, off-patent use sustains demand but presents regulatory and patent challenges. The drug's high prescription volume in countries like China and India, coupled with its relatively low-cost generic forms, enhances its ongoing revenue potential.

---

What Are the Patent and Regulatory Challenges Impacting Investment?

The original patent for Provigil expired in 2012, opening the market to generics. Teva, patent litigation, and potential regulatory restrictions influence future revenue streams. While Teva holds data exclusivity on certain formulations and methods of use, primary patent protections generally expire after 20 years from filing, which occurred in 1992.

Legal actions have sought to extend exclusivity via method-of-use patents or formulation patents, but courts have been cautious in granting new protections for off-label markets. Regulatory agencies, including the FDA, are increasingly scrutinizing off-label marketing practices.

In addition, government and health authority policies influence market dynamics, such as restrictions on prescribing off-label uses and international patent protections.

---

How Will Market Competition and Emerging Alternatives Affect the Investment Outlook?

Competition arises from multiple generic manufacturers offering modafinil at reduced costs. The price erosion risk remains significant in mature markets. However, newer wakefulness-promoting agents (e.g., armodafinil, solriamfetol, and pitolisant) target similar indications, often with improved pharmacokinetic profiles or lower side effect profiles.

Specific competitors include:

• Nuvigil (armodafinil): a stereoisomer of modafinil, marketed as having longer duration and lower side effects.
• Solriamfetol: approved for narcolepsy and sleep apnea-related hypersomnia, potentially cannibalizing Provigil’s market share.
• Pitolisant: FDA-approved for narcolepsy, offers a different mechanism of action with novel therapeutic niche.

Emerging developments in cognitive enhancement and military applications could drive additional off-label demand. However, the regulatory environment’s cautious stance limits aggressive expansion.

---

What Are Short-Term and Long-Term Investment Drivers and Risks?

Short-term drivers:

• Continued off-label use expanding demand.
• Entry into emerging markets such as China and India where affordable generics increase accessibility.
• Development of new formulations or combination therapies that prolong exclusivity periods.

Long-term risks:

• Patent expiry leading to price erosion and revenue decline.
• Regulatory restrictions on off-label marketing and use.
• Competition from novel agents with better safety or efficacy profiles.
• Market shifts toward non-pharmacological interventions for sleep and cognitive issues.

Investment strategies should incorporate diversification in wakefulness-promoting drug portfolios, recognition of patent expiration curves, and scrutiny of regulatory developments.

---

What Is the Future Outlook for Provigil and Similar Drugs?

The future depends on regulatory decisions and innovation within the sleep and cognitive disorder segments. Patent cliffs will continue to press brands toward pipeline innovation. Companies investing in next-generation wakefulness agents or combination treatments could define market leadership.

Off-label demand, while profitable, faces increasing regulatory oversight, limiting its growth potential. The broader market favors drugs with novel mechanisms, improved safety, and efficacy profiles.

Research and development into CNS drugs, personalized medicine, and digital therapeutics will influence the overall landscape, with proprietary formulations or delivery mechanisms offering potential for sustained revenue streams.

---

Key Takeaways

• Provigil's original patent expired in 2012; generics dominate the market with high volume but lower margins.
• Off-label use sustains demand but faces regulatory and legal limitations.
• Competition from newer wakefulness agents and generic entries compresss profit margins.
• Long-term growth hinges on pipeline innovation, new formulations, and regulatory navigation.
• Investment risk rises with patent expiration, regulatory changes, and market competition.

---

FAQ

1. How significant is off-label use in the overall market for modafinil?
Off-label use accounts for approximately 30-40% of total global sales, driven by demand in cognitive enhancement, military, and fatigue management sectors. Regulatory restrictions limit formal promotion for these indications.

2. What regulatory risks could impact future sales?
Potential risks include restrictions on off-label marketing, reclassification as a controlled substance, or new safety concerns leading to label changes.

3. Are there patent protections beyond the original patent for Provigil?
Secondary patents related to formulations or methods of use may provide limited exclusivity until their expiry, but major patent protections generally expired in 2012.

4. Which emerging drugs could replace Provigil in the future?
Drugs like solriamfetol and pitolisant, with different mechanisms and improved safety profiles, could capture market share.

5. How does the competitive environment influence investment decisions?
Price erosion from generics and competition from innovative agents necessitate a focus on pipeline development, patent strategies, and market diversification when evaluating investments.

---

References

1. IQVIA. "Pharmaceutical Market Data." 2022.
2. U.S. Food & Drug Administration. "Drug Approval Packages." 2015–2022.
3. Teva Pharmaceuticals. "Annual Reports and Financial Statements." 2011–2022.
4. MarketWatch. "Wakefulness-Promoting Drugs Market Analysis." 2023.
5. FDA. "Off-label Marketing and Promotion." 2022.